Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

BACKGROUND: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). METHODS: We investigated whether expression ratios of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Niewerth, Denise, Kaspers, Gertjan J. L., Jansen, Gerrit, van Meerloo, Johan, Zweegman, Sonja, Jenkins, Gaye, Whitlock, James A., Hunger, Stephen P., Lu, Xiaomin, Alonzo, Todd A., van de Ven, Peter M., Horton, Terzah M., Cloos, Jacqueline
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5011854/
https://ncbi.nlm.nih.gov/pubmed/27599459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0312-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados